ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

4 1. name of the medicinal product

Rapilysin 10 U

2. qualitative and quantitative composition

1 vial contains 0.56 g powder for solution for injection with 10 U reteplase (rINN). 1 prefilled syringe contains 10 ml water for injections. Potency of reteplase is expressed in units (U) by using a reference standard which is specific for reteplase and is not comparable with units used for other thrombolytic agents.

3. pharmaceutical form

Powder and solvent for solution for injection

4. clinical particulars

4.1 Therapeutic indication

Thrombolytic therapy of acute myocardial infarction (AMI) (within 12 hours after the onset of AMI symptoms)

4.2 Posology and method of administration

Reteplase is supplied as a freeze-dried substance in vials. The lyophilizate is reconstituted with the contents of the accompanying syringe (see chapter 6.6 Instructions for use and handling). The reconstituted solution should be used immediately.

Treatment with reteplase should be initiated as soon as possible after the onset of AMI symptoms. Reteplase is administered as a 10 + 10 U double bolus injection. Each bolus is administered as a slow intravenous injection over not more than 2 minutes. The second bolus is given 30 minutes after initiation of the first bolus injection. The bolus injection is given via an intravenous line. Ensure that the injection is not mistakenly given paravenously. Only clear, colourless solutions should be injected. No other medication should be added to the injection solution.

Heparin and acetylsalicylic acid should be administered concomitantly with and following the administration of reteplase to reduce the risk of rethrombosis. The recommended heparin dose is 5000 I.U. given as a bolus injection prior to reteplase therapy followed by an infusion of 1000 I.U. per hour starting after the second reteplase bolus. Heparin should be administered for at least 24 hours, preferably for 48 (-72) hours, aiming to keep aPTT values 1.5 to 2 times normal.

The initial dose of acetylsalicylic acid prior to thrombolysis should be at least 250 mg (250 - 350 mg) followed by 75 - 150 mg/day at least until discharge.

4.3 Contra-indications

Because thrombolytic therapy increases the risk of bleeding, reteplase is contra-indicated in the following situations: - known haemorrhagic diathesis - patients with current concomitant therapy with oral anticoagulants (e.g. warfarin 5 sodium) - intracranial neoplasm, arteriovenous malformation or aneurysm - neoplasm with increased bleeding risk - history of cerebrovascular accident - recent (< 10 days) prolonged and vigorous external heart massage - severe uncontrolled hypertension - active peptic ulceration - portal hypertension (oesophageal varices) - severe liver or renal dysfunction - acute pancreatitis, pericarditis, bacterial endocarditis - diabetic haemorrhagic retinopathy or other haemorrhagic ophthalmic conditions - within 3 months of severe bleeding, major trauma or major surgery (e.g. coronary artery bypass graft, intracranial or intraspinal surgery or trauma), obstetrical delivery, organ biopsy, previous puncture of noncompressible vessels

4.4 Special warnings and special precautions for use

Reteplase should be used by physicians experienced in the use of thrombolytic treatment and with the facilities to monitor that use. Each patient being considered for therapy with reteplase should be carefully evaluated.

Bleeding

The most common complication encountered during reteplase therapy is bleeding. The concomitant use of heparin anticoagulation may contribute to bleeding. As fibrin is lysed during reteplase therapy, bleeding from recent puncture sites may occur. Therefore, thrombolytic therapy requires careful attention to all possible bleeding sites (including catheter insertion sites, arterial and venous puncture sites, cutdown sites and needle puncture sites). The use of rigid catheter as well as intramuscular injections and nonessential handling of the patient should be avoided during treatment with reteplase.

Should serious bleeding, in particular cerebral haemorrhage, occur any concomitant heparin should be terminated immediately. In addition, the second bolus of reteplase should not be given if the serious bleeding occurs before it is administered. In general, however, it is not necessary to replace the coagulation factors because of the relatively short half-life of reteplase. Most patients who have bleeding can be managed by interruption of thrombolytic and anticoagulant therapy, volume replacement and manual pressure applied to an incompetent vessel. Protamine should be considered if heparin has been administered within 4 hours of the onset of bleeding. In the patients who fail to respond to these conservative measures, judicious use of transfusion products may be indicated. Transfusions of cryoprecipitate, fibrinogen, fresh frozen plasma and platelets should be considered with clinical and laboratory reassessment after each administration. A target fibrinogen level of 1 g/l is desirable with cryoprecipitate or fibrinogen infusion.

In the following conditions the risks of reteplase therapy may be increased and should be weighed against the anticipated benefits: - cerebrovascular disease - systolic blood pressure at entry >160 mmHg - recent gastrointestinal or genitourinary bleeding (within 10 days) - high likelihood of left heart thrombus, e.g. mitral stenosis with atrial fibrillation - septic thrombophlebitis or occluded arteriovenous cannula at seriously infected site - advanced age, i.e. over 75 years old - any other condition in which bleeding constitutes a significant hazard or would be particularly difficult because of its location

At present, no sufficient data in patients with a diastolic blood pressure >100 mmHg prior to thrombolytic therapy are available for reteplase. 6 Arrhythmias

Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is strongly recommended that antiarrhythmic therapy for bradycardia and/or ventricular tachyarrhythmias (e.g. ventricular tachycardia or fibrillation) be available when reteplase is administered.

7 Readministration

Since at present there is no experience with readministration of reteplase, the readministration is not recommended. However, no antibody formation to the reteplase molecule has been observed. If an anaphylactoid reaction occurs, the injection should be discontinued immediately and appropriate therapy should be initiated.

Use in children

Safety and effectiveness of reteplase in children have not been established. At present the administration of reteplase in children is not recommended.

4.5 Interaction with other medicinal products and other forms of interaction

No formal interaction studies with reteplase and drugs commonly administered in patients with AMI have been performed. Retrospective analyses of clinical studies did not reveal any clinical relevant interactions with drugs used concomitantly with reteplase in patients with acute myocardial infarction. Heparin, vitamin K antagonists and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole) may increase the risk of bleeding if administered prior to, during or after reteplase therapy.

Attention should be paid to this effect especially during periods of low plasma fibrinogen (up to about 2 days after fibrinolytic therapy of AMI)

4.6 Use during pregnancy and lactation

No experience in pregnant women is available for reteplase. Except in life-saving situations the use in pregnancy is contraindicated because animal studies have shown a risk of pregnancy loss; foetal effects have not been studied in animals and there are insufficient data on effects on postnatal development.

It is not known whether reteplase is excreted into breast milk. Breast milk should be discarded within the first 24 hours after thrombolytic therapy.

4.7 Effects on ability to drive and use machines

Not applicable

4.8 Undesirable effects

Haemorrhage The most frequent adverse drug reaction associated with reteplase treatment is haemorrhage, predominantly at the injection site, occasionally as gastrointestinal, gingival or genitourinary bleeding; haemopericardium, retroperitoneal bleeding, cerebral haemorrhage and epistaxis were observed rarely (each in less than 1%). Systolic blood pressure over 160 mmHg before thrombolysis with reteplase was associated with greater risk for cerebral bleeding. Blood transfusions were required rarely.

Cardiovascular As with other thrombolytic agents in the context of acute myocardial infarction, arrythmias (e.g. complete AV-block, ventricular tachycardia and fibrillation) and hypotension have been observed occasionally.

Hypersensitivity 8 Rarely allergic reactions have been reported. One anaphylactoid/anaphylactic reaction has been observed in the course of a clinical trial. 4.9

9 Overdose

In the event of overdosage one might expect depletion of fibrinogen and other blood coagulation components (e.g. coagulation factor V) with a consequent risk of bleeding.

Should serious bleeding, in particular cerebral haemorrhage, occur any concomitant heparin should be terminated immediately. In addition, the second bolus of reteplase should not be given if the serious bleeding occurs before it is administered. In general, however, it is not necessary to replace the coagulation factors because of the relatively short half-life of reteplase. Most patients who have bleeding can be managed by interruption of thrombolytic and anticoagulant therapy, volume replacement and manual pressure applied to an incompetent vessel. Protamine should be considered if heparin has been administered within 4 hours of the onset of bleeding. In the patients who fail to respond to these conservative measures, judicious use of transfusion products may be indicated. Transfusions of cryoprecipitate, fibrinogen, fresh frozen plasma and platelets should be considered with clinical and laboratory reassessment after each administration. A target fibrinogen level of 1 g/l is desirable with cryoprecipitate or fibrinogen infusion.

5. pharmacological properties

5.1 Pharmacodynamic properties

Reteplase is a recombinant plasminogen activator which catalyzes the cleavage of endogenous plasminogen to generate plasmin. This plasminogenolysis occurs preferentially by interaction with fibrin. Plasmin in turn degrades fibrinogen and fibrin, which is a component of the matrix of thrombi, thereby exerting its thrombolytic action.

Reteplase (10+10 U) dose-dependently reduces plasma fibrinogen levels by about 60 to 80%. The fibrinogen level normalizes within 2 days. As with other plasminogen activators a rebound phenomenon then occurs during which fibrinogen levels reach a maximum within 9 days and remain elevated for up to 18 days.

Reductions of plasma levels of plasminogen and α2-antiplasmin normalize within 1 to 3 days. Coagulation factor V, clotting factor VIII, α2-macroglobulin, and C1-esterase inhibitor are only slightly reduced and normalize within 1 to 2 days. Plasminogen activator inhibitor 1 (PAI-1) activity can be reduced to around zero, but rapidly normalizes within two hours showing a rebound phenomenon. Prothrombin activation fragment 1 levels and thrombin-antithrombin III-complexes increase during thrombolysis indicating thrombin production of which the clinical relevance is unknown.

A large comparative mortality trial (INJECT) in approx. 6000 patients showed that reteplase reduced the incidence of heart failure (secondary efficacy criterion) in a significant manner and was at least equally effective in terms of reducing mortality (primary efficacy criterion) when compared to streptokinase. In two clinical trials aiming primarily at patency (RAPID I and II) reteplase was associated with higher early patency rates (primary efficacy criterion), as well as with a lower incidence of heart failure (secondary efficacy criterion) than alteplase (3 hour and "accelerated" dosage regimes).

Pharmaco-therapeutic group: antithrombotic agent, ATC Code: B 01 A D

5.2 Pharmacokinetic properties

Following intravenous bolus injection of 10 + 10 U in patients with acute myocardial infarction reteplase antigen is distributed in plasma with a dominant half-life (t½α) of 18±5 min and eliminated 10 with a terminal half-life (t½ß) of 5.5 hours±12.5 min at a clearance rate of 121±25 ml/min. Reteplase activity is cleared from the plasma at a rate of 283±101 ml/min, resulting in a dominant half-life (t½α) of 14.6±6.7 min and a terminal half-life (t½ß) of 1.6 hours±39 min. Only minor amounts of reteplase were immunologically detected in the urine. Exact data of the main elimination routes for reteplase in humans are not available and the consequences of hepatic or renal insufficiency are not known. Experiments in rats indicate that the liver and the kidneys are the main organs of active uptake and lysosomal degradation.

Additional studies in human plasma samples in vitro suggest that complexation with C1-inactivator, α2-antiplasmin and α2-antitrypsin contributes to the inactivation of reteplase in plasma. The relative contribution of the inhibitors to inactivation of reteplase decreases as follows: C1-inactivator > α2- antiplasmin > α2-antitrypsin.

The half-life of reteplase was increased in patients with AMI as compared to healthy volunteers. An additional increase of half-life of activity in patients with myocardial infarction and severely impaired liver and renal function cannot be excluded, but no clinical data of pharmacokinetics of reteplase in these patients are available. Animal data show that in case of severely impaired renal function with a pronounced increase in serum creatinine and serum urea an increase in half-life of reteplase has to be expected. Mild impairment of renal function did not significantly affect the pharmacokinetic properties of reteplase.

5.3 Preclinical safety data

Acute toxicity studies have been performed in rats, rabbits and monkeys and subacute toxicity studies were performed in rats, dogs and monkeys. The predominant acute symptom after single high doses of reteplase in rats and rabbits was transient apathy shortly after injection. In cynomolgus monkeys, the sedative effect ranged from slight apathy to unconsciousness, caused by a reversible dose-related drop in blood pressure. There was increased local haemorrhage at the injection site. Subacute toxicity studies did not reveal any unexpected adverse events. In dogs repeated dosing of the human peptide reteplase led to immunologic-allergic reactions. Genotoxicity of reteplase was excluded by a complete battery of tests at different genetic end points in vitro and in vivo.

6. pharmaceutical particulars

6.1 List of excipients

Tranexamic acid, di-potassium-hydrogen phosphate, phosphoric acid, sucrose, polysorbate 80

6.2 Incompatibilities

None known to date.

6.3 Shelf-life

Reteplase 10 U vials have a shelf-life of 1 year at temperatures of 2°C to 25°C when stored in the original pack. When reconstituted as directed, the solution should be used immediately. Chemical stability has been proven for 4 hours.

6.4 Special precautions for storage

Protect the lyophilizate during extended storage from excessive exposure to light.

11 6.5 Nature and content of container

2 vials with powder for solution for injection 2 syringes with solvent 2 reconstitution devices and 2 needles 19 G 1. 6.6

12 Instructions for use, handling and disposal (if appropriate)

1. Use aseptic technique throughout. 2. Remove the protective flip-cap from the vial of reteplase and clean the rubber closure with an alcohol wipe. 3. Open the package containing the reconstitution spike, remove the protective cap from the Luer lock port of the reconstitution spike. 4. Open the package containing the 10 ml syringe with Luer tip. Remove the tip cap from the syringe. 5. Remove the protective cap from the spike end of the reconstitution spike and insert the spike through the rubber closure into the vial of reteplase. Connect the syringe to the reconstitution spike and transfer the 10 ml of solvent into the vial of reteplase. 6. With the reconstitution spike and syringe still attached to the vial, swirl the vial gently to dissolve the reteplase powder. DO NOT SHAKE. The reconstituted preparation results in a clear, colourless solution. 7. Withdraw 10 ml of reteplase solution back into the syringe. A small amount of solution may remain in the vial due to overfill. 8. Disconnect the syringe from the reconstitution spike and attach the sterile needle provided. The dose is now ready for intravenous administration.

7. MARKETING AUTHORIZATION HOLDER

Boehringer Mannheim GmbH Sandhofer Straße 116 D-68298 Mannheim

8. Number(s) in the Community register of medicinal products

EU/1/96/018/001

9. DATE OF FIRST AUTHORIZATION/RENEWAL OF THE AUTHORIZATION

29 August 1996

10. DATE OF REVISION OF TEXT

13 ANNEX III

14 A. Labelling

15 Manuscript of Rapilysin 10 U Label

Rapilysin 10 U

Powder for solution for i.v. injection 10 U reteplase Use immediately after reconstitution Lot/Batch: EXP:

Boehringer Mannheim GmbH, D-68298 Mannheim ______

16 Manuscript of Rapilysin 10 U Carton box

Rapilysin 10 U

Powder and solvent for solution for intravenous injection Active ingredient: reteplase Recombinant plasminogen activator, thrombolytic agent 1 vial contains 0,56 g powder for solution for injection with 10 U reteplase and 8.0 mg tranexamic acid, 131.0 mg di-potassium-hydrogen phosphate, 49,3 mg phosphoric acid, 350.0 mg sucrose and 5.0 mg polysorbate 80 as constituents. 1 prefilled syringe contains 10 ml water for injections. 2 vials with powder for solution for injection 2 syringes with solvent 2 reconstitution spikes 2 needles 19G1 Use immediately after reconstitution Protect from light Store at + 2 ° C to + 25 ° C Keep all medicines out of the reach of children! Medicinal product subject to medical prescription. Please read the user information! Marketing authorization No.: Lot/Batch: EXP:

Boehringer Mannheim GmbH, D-68298 Mannheim ______

17 B. Package leaflet

18 User Information - please read carefully

Rapilysin 10 U

Powder and solvent for solution for intravenous injection

Composition

- Pharmacologically active constituents 1 vial contains 0.56 g powder for solution for injection with 10 U reteplase. - Other constituents Tranexamic acid, di-potassium-hydrogen phophate, phosphoric acid, sucrose, polysorbate 80 1 prefilled syringe contains 10 ml water for injections

Pharmaceutical form and contents

Powder for solution for intravenous injection after the compound has been dissolved in the supplied solvent (water for injections). Rapilysin 10 U is supplied as a pack containing 2 vials with powder for solution for injection, 2 syringes with solvent, 2 reconstitution devices and 2 needles.

Pharmaco-therapeutic group and type of activity

Reteplase (a recombinant plasminogen activator) is an agent designed to dissolve blood clots and thus restore blood flow in obstructed vessels (=thrombolysis).

Marketing authorisation holder and manufacturer

Boehringer Mannheim GmbH Sandhofer Str. 116 D 68298 Mannheim Germany

Indication

Thrombolytic therapy of acute myocardial infarction (AMI) within 12 hours after the onset of AMI symptoms (dissolution of blood clots that have caused an acute myocardial infarction by obstructing coronary arteries)

Contra-indications

Because thrombolytic therapy increases the risk of bleeding, Rapilysin 10 U must not be used in the following situations:

- Predisposition to haemorrhaging - When substances which prevent blood clotting (oral anticoagulants) are also being given (e.g. warfarin, coumarin) - Presence of a brain tumour, blood vessel malformation and/or vessel wall dilatation (aneurysm) 19 - Presence of tumours associated with an increased risk of bleeding - History of cerebrovascular accident (e.g. stroke) - Recent (<10 days) prolonged and vigorous external heart massage - Severe, uncontrolled high blood pressure (hypertension) - Presence of ulcer in the stomach or small intestine - Varices in the oesophagus (frequently associated with liver cirrhosis) - Severe liver or kidney failure - Acute inflammation of the pancreas or pericardium (the fibroserous sac surrounding the heart), bacterial inflammation of the endocardium (innermost layer of the heart) - Diabetic disease of the retina or other eye conditions predisposing to bleeding - Any of the following within the last 3 months: severe bleeding, major trauma, major surgery (e.g. coronary artery bypass graft, intracranial or intraspinal surgery or trauma), obstetrical delivery, organ biopsy or previous puncture of noncompressible vessels.

Special warnings and precautions for use

• Bleeding The most common complication encountered during Rapilysin 10 U therapy is bleeding. Careful attention should be paid to all possible bleeding sites (e.g.blood vessel puncture sites). Simultaneous treatment with heparin may also promote bleeding.

In the following conditions the risks of reteplase therapy may be increased and should be weighed against the anticipated benefits: - Vascular diseases of the brain - Systolic blood pressure >160 mmHg before treatment - Recent (within 10 days) bleeding in the gastrointestinal or urogenital tract - High likelihood of a blood clot in the left heart (e.g. as a result of narrowing of the mitral valve with fibrillation of the upper heart chambers) - Septic thrombophlebitis (inflammation of a vein associated with thrombus formation) or occluded arteriovenous fistula at seriously infected site - Advanced age, i.e. over 75 years old - Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to control because of its location.

At present, there is insufficient data available on patients with elevated diastolic blood pressure of >100 mmHg before treatment with Rapilysin 10 U.

• Arrhythmias (abnormal heart rhythm) Thrombolytic therapy may be associated with arrhythmias. Hence, adaequate precautions for treating the latter should be taken.

• Readministration Since at present there is no experience with readministration of Rapilysin 10 U, the readministration is not recommended. However, no antibody formation to the reteplase molecule has been observed.

• Pregnancy and lactation There is no experience with Rapilysin 10 U in pregnant women. Except in life-saving situations the use in pregnancy is contraindicated. It is not known whether Rapilysin 10 U is excreted into mother`s milk. Mother`s milk

20 hould be discarded within the first 24 hours after thrombolytic therapy.

• Use in children Safety and effectiveness of Rapilysin 10 U in children have not been established. Treatment of children with Rapilysin 10 U is not recommended.

Interactions

Heparin and other substances which prevent blood clotting (anticoagulants) as well as drugs that alter platelet function (such as aspirin) may increase the risk of bleeding if administered before, during or after Rapilysin 10 U therapy.

Recommended dose and method of administration

Rapilysin 10 U is usually administered in a hospital setting. The drug is supplied as a powder for injection in vials. The active ingredient is reconstituted with the contents of the accompanying syringe. The reconstituted solution should be used immediately. Treatment with Rapilysin 10 U should be initiated as soon as possible after the onset of symptoms related to an acute myocardial infarction. Rapilysin 10 U is administered as two separate 10 + 10 U double bolus intravenous injections, 30 minutes apart. Each bolus should be given slowly over not more than 2 minutes. According to the physician`s instructions, heparin (usually 5000 I.U. as a bolus injection followed by an infusion of 1000 I.U. per hour) and aspirin (initial dose of 250 - 350 mg followed by 75 - 150 mg/day) should be administered concomitantly with and following the administration of Rapilysin 10 U to reduce the risk of reclotting (rethrombosis).

Overdosage

In the event of overdosage there may be an increased risk of bleeding.

Undesirable effects

• Haemorrhage (bleeding) The most frequent adverse drug reaction associated with Rapilysin 10 U treatment is bleeding, predominantly at the injection site, occasionally in the gastrointestinal tract (stomach, gut), gum or urogenital tract; pericardial, retroperitoneal, cerebral and nasal bleeding were observed rarely (each in less than 1%). Systolic blood pressure over 160 mmHg before thrombolysis with reteplase was associated with greater risk for cerebral bleeding. Blood transfusions were required rarely.

• Cardiovascular As with other thrombolytic agents used to treat acute myocardial infarction, relevant disturbances of heart rhythm and low blood pressure have been observed occasionally.

• Hypersensitivity Rarely allergic reactions have been reported. In one case a severe hypersensitivity reaction (anaphylactic reaction) has been observed in the course of a clinical trial. Patients are requested to inform their physician or pharmacist if undesirable effects occur, in particular if they are not listed in this package insert.

Shelf-life

The shelf-life of the vials is printed on the folding box and on the labels. Do not use 21 the vials after this date! When reconstituted as directed, the solution should be used immediately. Chemical stability has been proven for 4 hours.

Special precautions for storage

The powder for injection must be protected from excessive exposure to light during extended storage.

Date of the information

22 Instructions for use/handling

1. Use aseptic technique throughout. 2. Remove the protective flip-cap from the vial of Rapilysin 10 U and clean the rubber closure with an alcohol wipe. 3. Open the package containing the reconstitution spike, remove the protective cap from the Luer lock port of the reconstitution spike. 4. Open the package containing the 10 ml syringe with Luer tip. Remove the tip cap from the syringe. 5. Remove the protective cap from the spike end of the reconstitution spike and insert the spike through the rubber closure into the vial of reteplase. Connect the syringe to the reconstitution spike and transfer the 10 ml of solvent into the vial of reteplase. 6. With the reconstitution spike and syringe still attached to the vial, swirl the vial gently to dissolve the reteplase powder. DO NOT SHAKE. The reconstituted preparation results in a clear, colourless solution. 7. Withdraw 10 ml of Rapilysin 10 U solution back into the syringe. A small amount of solution may remain in the vial due to overfill. 8. Disconnect the syringe from the reconstitution spike and attach the sterile needle provided. The dose is now ready for intravenous administration.

23 Other information

For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.

Belgique/België: Boehringer Mannheim Belgium SA/NV Avenue des Croix de Guerre 90, Oorlogskruisenlaan 90,

1120 Bruxelles - Brussel, Tel.: +32 2-247 47 47

Danmark: Boehringer Mannheim Promotional Office Slotsmarken 17, 2970 Hørsholm, Tel.: +45 45 16 09 30

Deutschland: Boehringer Mannheim GmbH Sandhofer Str. 116, 68305 Mannheim, Tel.: +49 621-759-0

EΛΛA∆A: Farmalex S.A., P.O. Box 14015 Tsocha 15-17, 11510 Athens Tel:+30 1 64 45 612

España: Boehringer Mannheim S.A. Copérnico, 60 y 61-63, 08006 Barcelona, Tel.: +34 3 201 44 11

France: Boehringer France Pharma SA 89, bd Franklin Roosevelt, 92563 Rueil-Malmaison Cedex, Tel.: +33 1 47 14 89 01

Ireland: Boehringer Mannheim UK Limited, Simpson Parkway,Kirkton Campus, Livingston, West Lothian EH54 7BH, Tel.: +44 1506 412512

Italia: Boehringer Mannheim Italia SpA Viale G.B. Stucchi 110, 20052 Monza, Tel: +39 39 2471

Luxembourg: Boehringer Mannheim GmbH Sandhofer Strasse 116, 68305 Mannheim, Tel.: +49 621 759 0

Nederland: Boehringer Mannheim BV, Postbus 1007,1300 BA Almere Markerkant 10-13, 1314 AN Almere, Tel.: +31 36-5394911

Österreich: Boehringer Mannheim GmbH, Wien Engelhorngasse 3, 1211 Wien, Tel.: +43 1-27787-0

Portugal: Laboratórios Boehringer Mannheim de Portugal, Lda Rua da Barruncheira, 6, Carnaxide, Apartado 46, 2796 Linda-a-Velha, Tel.: +351 1 417 17 17

Suomi: Orion-yhtmä Oy Orionintie 1, 02200 Espoo, PL 65, 02101 Espoo, Puh: +358 9 4291

24 Sverige: Boehringer Mannheim Scandinavia AB Karlsbodavägen 30, 161 26 Bromma, Tel.: +46 84 04 88 00

United Kingdom: Boehringer Mannheim UK Limited Simpson Parkway,Kirkton Campus, Livingston,West Lothian,EH54 7BH, Tel.: +44 1506 412512

Keep all medicines out of the reach of children!

25